A Phase 3 interventional study of Vortioxetine in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 31 sites in 13 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-24.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 42nd largest by enrollment, is one of 3 that started in 2017, is one of 31 in phase 3, and was the 42nd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2017, is one of 21 in phase 3, and was the 30th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
Drug: Vortioxetine
Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Also known as: Brintellix, Lu AA21004
Incidence of Treatment-Emergent Adverse Events (Safety)
Based on safety assessments (e.g. paediatric adverse event rating scale (PAERS), clinical safety laboratory tests (including reproductive hormones), vital signs, weight, height, Tanner score, menstrual cycle, ECG, and C-SSRS
Time frame: Up to Week 104
Change in CDRS-R total score
Children Depression Rating Scale, revised version
Time frame: Change from study 12712A baseline to Week 104
Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)
Number of relapses (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)
Time frame: Up to Week 104
Loss of remission (CDRS-R <28 with a history of 2 weeks of clinical deterioration)
Loss of remission (CDRS-R \<28 with a history of 2 weeks of clinical deterioration)
Time frame: Up to Week 104
Change in CGI-S score
Clinical Global Impression - Severity of Illness
Time frame: Change from study 12712A baseline to Week 104
CGI-I score
Clinical Global Impression - Global Improvement
Time frame: Week 104
Children (7-11 years): change in BRIEF using the Global Executive Composite score
Behaviour Rating Inventory of Executive Function
Time frame: Change from study 12712A baseline to Week 104
Children (7-11 years): change in BRIEF using the Megacognition Index
Behaviour Rating Inventory of Executive Function
Time frame: Change from study 12712A baseline to Week 104
Adolescents (12-17 years): change in BRIEF-SR using the Global Executive Composite score
Behaviour Rating Inventory of Executive Function, Self-report version
Time frame: Change from study 12712A baseline to Week 104
Adolescents (12-17 years): change in BRIEF-SR using the Megacognition Index
Behaviour Rating Inventory of Executive Function, Self-report version
Time frame: Change from study 12712A baseline to Week 104
Change in CGAS score
Children's Global Assessment Scale
Time frame: Change from study 12712A baseline to Week 104
Change in PedsQL VAS score
Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales
Time frame: Change from study 12712A baseline to Week 104
Ran from Mar 2017 to primary completion in Apr 2020, 37 months.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 37 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine